Results 11 to 20 of about 49,053 (243)
mBio, 2017 Resistance to the integrase strand transfer inhibitors raltegravir and elvitegravir is often due to well-identified mutations in the integrase gene. However, the situation is less clear for patients who fail dolutegravir treatment.
Isabelle Malet +7 more
doaj +2 more sources
Comparative biochemical analysis of HIV-1 subtype B and C integrase enzymes [PDF]
Retrovirology, 2009 Background Integrase inhibitors are currently being incorporated into highly active antiretroviral therapy (HAART). Due to high HIV variability, integrase inhibitor efficacy must be evaluated against a range of integrase enzymes from different subtypes ...
Kuhl Björn D +7 more
doaj +2 more sources
Variable orthogonality of serine integrase interactions within the ϕC31 family [PDF]
Scientific ReportsSerine integrases are phage- (or mobile element-) encoded enzymes that catalyse site-specific recombination reactions between a short DNA sequence on the phage genome (attP) and a corresponding host genome sequence (attB), thereby integrating the phage ...
Alasdair I. MacDonald +6 more
doaj +4 more sources
Integrase and integration: biochemical activities of HIV-1 integrase [PDF]
Retrovirology, 2008 Integration of retroviral DNA is an obligatory step of retrovirus replication because proviral DNA is the template for productive infection. Integrase, a retroviral enzyme, catalyses integration. The process of integration can be divided into two sequential reactions.
Deprez Eric +4 more
openaire +3 more sources
EMBO reports, 2010 Antiretroviral drugs to prevent integration of the HIV viral genome into chromosomes are undergoing clinical trials, yet they have been developed with an imperfect understanding of their mechanism of action. The recent crystal structure of the major viral protein integrase from a related, little‐known retrovirus, has finally provided insight into how ...
openaire +2 more sources
Resistance to Integrase Inhibitors [PDF]
Viruses, 2010 Integrase (IN) is a clinically validated target for the treatment of human immunodeficiency virus infections and raltegravir exhibits remarkable clinical activity. The next most advanced IN inhibitor is elvitegravir. However, mutant viruses lead to treatment failure and mutations within the IN coding sequence appear to confer cross-resistance.
Mathieu Métifiot +3 more
openaire +3 more sources
Synthesis of programmable integrases [PDF]
Proceedings of the National Academy of Sciences, 2009 Accurate modification of the 3 billion-base-pair human genome requires tools with exceptional sequence specificity. Here, we describe a general strategy for the design of enzymes that target a single site within the genome. We generated chimeric zinc finger recombinases with cooperative DNA-binding and catalytic specificities that integrate transgenes ...
Russell M, Gordley +2 more
openaire +2 more sources
Genetic Diversity and Low Therapeutic Impact of Variant-Specific Markers in HIV-1 Pol Proteins
Frontiers in Microbiology, 2022 The emergence and spread of new HIV-1 variants pose a challenge for the effectiveness of antiretrovirals (ARV) targeting Pol proteins. During viral evolution, non-synonymous mutations have fixed along the viral genome, leading to amino acid (aa) changes ...
Paloma Troyano-Hernáez +2 more
doaj +1 more source
Retroviral Integrase: Then and Now [PDF]
Annual Review of Virology, 2015 The retroviral integrases are virally encoded, specialized recombinases that catalyze the insertion of viral DNA into the host cell's DNA, a process that is essential for virus propagation. We have learned a great deal since the existence of an integrated form of retroviral DNA (the provirus) was first proposed by Howard Temin in 1964. Initial studies
Mark D, Andrake, Anna Marie, Skalka
openaire +2 more sources
Resistance to inhibitors of the human immunodeficiency virus type 1 integration
Brazilian Journal of Infectious Diseases, 2010 This review will summarize the role of integrase in HIV-1 infection, the mechanism of integrase inhibitors and resistance with an emphasis on raltegravir (RAL), the first integrase inhibitor licensed to treat HIV-1 infection.
Daria J. Hazuda, PhD
doaj +1 more source